+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients



Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients



American Journal of Medicine 100(4): 412-417



To examine the mechanism of the decreased frequency of severe hypoglycemia with implantable pump therapy compared with subcutaneous intensive therapy. Eight subjects with insulin-dependent diabetes mellitus (IDDM), enrolled in an implantable insulin pump study, were admitted to the General Clinical Research Center and on 2 separate days were given either a dose of preprandial insulin chosen to maintain normoglycemia for a standard (450 kcal, 50% carbohydrate) breakfast or 1.75 times the dose. The two doses were administered subcutaneously (by syringe or with an external pump) during one inpatient admission and by implantable pump (intraperitoneally, n=6; or intravenously, n=2) during a separate admission. Blood glucose, plasma-free insulin, and neurocognitive function were measured for 4 hours after the meal. Subcutaneous administration resulted in 7 episodes of hypoglycemia (2 with the usual dose and 5 with the 1.75-fold dose), defined as blood glucose less than 50 mg/dL; implantable pump treatment resulted in only 2 episodes, both with the 1.75-fold dose (P <0.05, Fisher's two-tailed test for implantable versus subcutaneous). Compared with subcutaneous delivery, implantable pump therapy provided significantly lower insulin levels during the final 2 hours after administration of the usual dose and the 1.75-fold dose (P <0.005). In addition to the decreased frequency of hypoglycemia, implantable pump therapy resulted in significantly lower area under the glycemia curve during the first 120 minutes with the 1.75-fold dose compared with subcutaneous administration. The lower frequency of severe hypoglycemia with intensive therapy administered by implantable pump therapy is explained by the more rapid clearance of insulin delivered intraperitoneally or intravenously compared with intensive subcutaneous injection regimens. The lower frequency of severe hypoglycemia with implantable pump therapy compared with subcutaneous therapy demonstrated in clinical trials is confirmed by this study, in which we attempted to induce hypoglycemia.

(PDF emailed within 0-6 h: $19.90)

Accession: 009944140

Download citation: RISBibTeXText

PMID: 8610727

DOI: 10.1016/S0002-9343(97)89516-2


Related references

Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA 276(16): 1322-1327, 1996

Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocrine Practice 3(5): 281-283, 2004

Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery. Transplantation Proceedings 27(6): 3329-3330, 1995

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Archives of Internal Medicine 157(11): 1249-1255, 1997

Adverse effects of insulin antibodies on postprandial plasma glucose and insulin profiles in diabetic patients without immune insulin resistance. Implications for intensive insulin regimens. Diabetes 36(3): 305-309, 1987

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine 157(11): 1249-1255, 1997

Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstetrics and Gynecology 85(3): 417-422, 1995

Comparison of plasma insulin profiles after subcutaneous administration of insulin by jet spray and conventional needle injection in patients with insulin-dependent diabetes mellitus. Mayo Clinic Proceedings 59(11): 751-754, 1984

Plasma insulin profiles after intravenous or subcutaneous administration in non insulin dependent diabetes mellitus patients requiring insulin treatment the role of obesity. Diabetes Research & Clinical Practice (SUPPL 1): S172-S173, 1985

Insulin-dependent diabetes mellitus: subcutaneous insulin therapy with a portable infusion pump. Medicina Clinica 80(9): 394-397, 1983

Plasma catecholamine responses to hypoglycemia in children with insulin dependent diabetes mellitus effect of intensive insulin therapy. Pediatric Research 20(4 PART 2): 330A, 1986

Intensive control of insulin dependent diabetes mellitus by insulin pump therapy in Alaska, USA. FAR EAST BRANCH-RUSSIAN ACADEMY OF SCIENCES AND AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE [Author] Bridges of the science between North America and the Russian Far East 2) 187, 1994

Intensified insulin therapy improved metabolic control without changes of hypoglycemia in 64 insulin treated patients with non insulin dependent diabetes mellitus. Diabetologia 40(SUPPL 1): A339, 1997

Comparison of glucose control and hypoglycemia risk in patients with type i diabetes mellitus on conventional vs. intensive vs. continuous subcutaneous insulin infusion therapy. Diabetes Research & Clinical Practice (SUPPL 1): S211-S212, 1985

Efficacy and safety of inhaled insulin compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes Results of a 6-month, randomised, comparative trial. Diabetologia 45(Supplement 2): A 17, August, 2002